Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

Recently, Tempus AI TEM updated its sales guidance for 2025. It did so for the second time within six months, backed by a strong second-quarter performance. Full-year revenues are now expected to be ...

The stock soared after investors heard that update. Exponential revenue increases are being driven by its burgeoning AI infrastructure services. Just as importantly for investors, Nebius has a solid ...

Although many artificial intelligence (AI) stocks have performed well since "Liberation Day" on April 2, the rough start to ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

In a report released today, Rachel Vatnsdal from J.P. Morgan maintained a Hold rating on Tempus AI, Inc. Class A, with a price target of $60.00. The company’s shares closed last Friday at $60.87. Take ...

In a report released on August 8, Subbu Nambi from Guggenheim reiterated a Buy rating on Tempus AI, Inc. Class A, with a price target of $75.00. The company’s shares closed last Friday at $60.87.

Alphabet, UnitedHealth Group, Salesforce, Oracle, ServiceNow, Palo Alto Networks, and Tempus AI are the seven Healthcare ...

U.S. President Donald Trump launched a scathing attack on former House speaker Nancy Pelosi and her husband Paul Pelosi, on ...

Shares in health technology group Tempus AI ($TEM) raced 7% higher today after its Q2 revenues surged on cancer testing demand. Forecast Busting ...

The stock of Tempus AI (NASDAQ: TEM) gave back some of its gains after surging early in Friday's trading, but it still ended ...